TrialAssure, a global software company focused on developing clinical trial transparency tools-announced the full release of ANONYMIZE DS, the new software-as-a-service (SaaS) application that utilizes automation to anonymize sponsor’s clinical trial data, during the DIA Global Clinical Trial Disclosure and Data Transparency Conference. Gathering user feedback since its limited release February 2019, TrialAssure ANONYMIZE DS is now fully available to the public.
“As one of the first groups to automate the anonymization of datasets, our developers heard first-hand feedback from industry users during the limited release of the product and fine-tuned ANONYMIZE DS to best meet their needs,” says Zach Weingarden, Product Solutions Manager, TrialAssure. “As with all software we develop, our development team is open to engaging end users, actively encouraging feedback and listening carefully to their suggestions.”
Key features of TrialAssure ANONYMIZE DS, include:
“All pharmaceutical sponsors will need to rely on anonymization methods, and therefore tools, to stay ahead of transparency regulations, as redaction of data limits data utility,” says Mohamad Zahreddine, CIO, TrialAssure, and member of the Forbes Technology Council. “Transparency experts and thoughtful developers have banded together, utilizing the latest technology to build a software application that is of great importance to the future of the pharmaceutical industry, and more broadly, all those in clinical research. We want global teams to #BeTransparent, and it’s in everyone’s best interest that while we must first protect privacy, the data shared should be usable.”
Final ENLIVEN Trial Results Confirm Long-Term Benefit of Turalio in Tenosynovial Giant Cell Tumor
July 9th 2025In final data from the Phase III ENLIVEN study, Turalio (pexidartinib) demonstrated durable tumor responses and a consistent safety profile in patients with symptomatic TGCT not amenable to surgery.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
Effect of AI/ML, Real World Evidence and Master Protocols on Trial Success
July 7th 2025How the application of artificial intelligence, broader use of real-world evidence, decentralized clinical trials, master protocols, and risk-based quality monitoring, together with strong ethical oversight and increased collaboration, are contributing to better healthcare delivery and strengthening the role of clinical research in driving global health progress.